As more effective therapeutic strategies are urgently needed for treating hepatic fibrosis and cirrhosis, inhibition of TBK1 and IKKε by amlexanox may be a promising therapeutic strategy to cure fibrosis, which could allow for remodelling and regression of fibrosis. Here, IKBKE is linked to fibrosis.